SAB Biotherapeutics (SABS) has provided an update.
SAB Biotherapeutics, Inc. has appointed Dr. Jay S. Skyler as a Class I director, effective May 3, 2024. With no disclosed conflicts of interest or familial ties to the company’s current leadership, Dr. Skyler brings a wealth of experience from his medical and academic career, including significant roles in diabetes research and positions on the boards of various public companies. His expertise is expected to be a valuable asset to the board, reflecting his distinguished career in the life sciences sector.
Find detailed analytics on SABS stock on TipRanks’ Stock Analysis page.
